NCT06295770 Obinutuzumab in Treatment of Fibrillary Glomerulonephritis Status RECRUITING Phase PHASE2
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06284122 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Status RECRUITING Phase PHASE3
NCT06265220 AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06252675 Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06213311 A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06192888 A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Status RECRUITING Phase PHASE3
NCT06175000 Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Status RECRUITING Phase PHASE2
NCT06120673 REmission in Membranous Nephropathy International Trial (REMIT) Status WITHDRAWN Phase PHASE3
NCT06108232 Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06084936 A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma Status RECRUITING Phase PHASE3
NCT06073821 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06071871 A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma Status RECRUITING Phase PHASE2
NCT06054776 Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06043674 Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation Status RECRUITING Phase PHASE2
NCT05968001 Obinutuzumab in Chinese Real-world Patients With iNHL Status NOT_YET_RECRUITING Phase N/A
NCT05950997 A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL Status RECRUITING Phase NA
NCT05943496 Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Status RECRUITING Phase PHASE1
NCT05899621 A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL Status RECRUITING Phase N/A